Mycosis Fungoides Therapeutics Market

Global Mycosis Fungoides Therapeutics Market Size, Share & Trend Analysis Report, By Type (Small Molecules and Biologics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), Forecast (2021-2027)

Published: Jan 2022 | Report Code: OMR2025373 | Category : Pharmaceuticals | Delivery Format: /

The global mycosis fungoides therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Mycosis fungoides is the most common type of blood cancer known as cutaneous T-cell lymphoma. Cutaneous T-cell lymphoma occurs when certain T-cells become cancerous. These cancers affect the skin and cause different types of lesions on the skin. Mycosis fungoides usually affects adults over age 50. 

An increase in prevalence and incidence of mycosis fungoides and new drug approvals accelerate the global mycosis fungoides therapeutics market during the forecast period. In addition, special drug designation for mycosis fungoides drugs is another major factor for the demand of the global mycosis fungoides therapeutics market during the forecast period.

The global mycosis fungoides therapeutics market analysis includes some of the key market players such as Azurity Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Kyowa Kirin Co., Ltd., among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in June 2021, Innate Pharma SA announced preliminary data from the mycosis fungoides (MF) cohort of Phase 2 TELLOMAK clinical trial, evaluating lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, in an oral presentation at the 16th International Conference on Malignant Lymphoma (16-ICML).

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: Azurity Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Kyowa Kirin Co., Ltd., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Mycosis Fungoides Therapeutics Market by Segment

By Type 

Small Molecules

Biologics

By Distribution Channel 

Hospital Pharmacies

Retail Pharmacies

Others

Global Mycosis Fungoides Therapeutics Market by Regional Analysis

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World